Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
253.34
+5.91 (2.39%)
Delayed:   1:19PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 250.75 - 257.10
52 week 116.01 - 263.91
Open 250.86
Vol / Avg. 262,312.00/476,361.00
Mkt cap 85.37B
P/E 75.17
Div/yield     -
EPS 3.37
Shares 334.40M
Beta 0.35
Inst. own 85%
May 20, 2015
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 6, 2015
Q1 2015 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 23, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Call
Feb 22, 2015
Q4 2014 Valeant Pharmaceuticals International Inc Earnings Release
Jan 13, 2015
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference Q&A session
Jan 13, 2015
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference
Jan 8, 2015
Valeant Pharmaceuticals International Inc 2015 Financial Guidance Call
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 23.43% 11.04%
Operating margin 26.68% 23.11%
EBITD margin - 55.83%
Return on average assets 8.02% 3.36%
Return on average equity 41.12% 17.52%
Employees 16,800 -
CDP Score - -

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 54
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Age: 52
Pavel Mirovsky President and General Manager - Europe
Age: 63
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development
Age: 43
Ari Kellen Executive Vice President, Company Group Chairman
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 43
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 38
Ryan H. Weldon Executive Vice President, Company Group Chairman
Age: 36
Robert A. Ingram Lead Independent Director
Age: 72
Jeffrey W. Ubben Director
Age: 54